Autoinflammatory diseases: An update of clinical and genetic aspects

Rheumatology

Volumn 47, Issue 7, 2008, Pages 946-951

  Yao, Q ^a   Furst, D E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloidosis; Autoinflammatory disease; Cryopyrin; Familial Mediterranean fever; Genetic analysis; Hyperimmunoglobulinemia D periodic fever syndrome; Interleukin 1 receptor antagonist; Therapy; TNF blocker; Tumour necrosis factor a receptor associated periodic fever syndrome

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA INTERFERON; COLCHICINE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIMVASTATIN; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; AMYLOIDOSIS; ARTHRALGIA; ARTHRITIS; AUTOINFLAMMATORY DISEASE; CLINICAL FEATURE; CLINICAL GENETICS; CLINICAL TRIAL; CRYOPYRIN ASSOCIATED PERIODIC FEVER SYNDROME; DIARRHEA; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; GENETIC ANALYSIS; HEREDITARY PERIODIC FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOGLOBULIN DEFICIENCY; LABORATORY TEST; MEDICAL LITERATURE; MOUTH ULCER; MUCKLE WELLS SYNDROME; MUTATIONAL ANALYSIS; NEPHRITIS; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENT FEVER; REVIEW; SCROTAL PAIN; SCROTAL SWELLING; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ADULT; CARRIER PROTEINS; DIAGNOSIS, DIFFERENTIAL; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEVALONATE KINASE DEFICIENCY; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 45749155618     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken118     Document Type: Review

References (82)

1. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: Evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006;18:108-17.
2. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007;13:38-40.
3. Samuels J, Aksentijevich I, Torosyan Y et al. Familial Mediterranean fever at the millennium: Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 1998;77:268-97.
4. Lidar M, Livneh A. Familial Mediterranean fever: Clinical, molecular and management advancements. Neth J Med 2007;65:318-24.
5. Ozçakar ZB, Yalçinkaya F, Yüksel S, Ekim M. The expanded clinical spectrum of familial Mediterranean fever. Clin Rheumatol 2007;26:1557-60.
6. Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A. Attacks of pericarditis as a manifestation of familial Mediterranean fever. Q J Med 1997;90:643-7.
7. Lachmann HJ, Goodman HJ, Andrews PA et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: A report of two cases. Arthritis Rheum 2006;54:2010-4.
8. Uthman I, El-Sayyad J, El-Jajj I, Bizr iA-R. Familial Mediterranean fever mimicking septic arthritis. Rheum Int 2005;25:633-4.
9. Garcia-Gonzalez A, Weisman MH. The arthritis of familial Mediterranean fever. Semin Arthritis Rheum 1992;22:139-50.
10. Kaushansky K, Finerman GA, Schwabe AD. Chronic destructive arthritis in familial Mediterranean fever: The predominance of hip involvement and its management. Clin Orthop Relat Res 1981;155:156-61.
11. Herness D, Makin M. Articular damage in familial Mediterranean fever. Report of four cases. J Bone Joint Surg Am 1975;57:265-7.
12. Brodey PA, Wolff SM. Radiographic changes in the sacroiliac joints in Familial Mediterranean fever. Radiology 1975;114:331-3.
13. Ozel AM, Demirtürk L, Yazgan Y et al. Familial Mediterranean fever. A review of the disease and clinical and laboratory findings in 105 patients. Digest Liver Dis 2000;32:504-9.
14. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997;90:797-807.
15. A candidate gene for familial Mediterranean fever. The French FMF Consortium. Nat Genet 1997;17:25-31.
16. Sarrauste de Menthière C, Terrière S, Pugnère D, Ruiz M, Demaille J, Touitou I. INFEVERS: The registry for FMF and hereditatory inflammatory disorders mutations. Nucleic Acids Res 2003;31:282.
17. Eisenberg S, Aksentijevich I, Deng Z, Kastner DL, Matzner Y. Diagnosis of familial Mediterranean fever by molecular genetics method. Ann Intern Med 1998;129:539.
18. Schaner PE, Gumucio DL. Familial Mediterranean fever in the post-genomic era: How an ancient disease is providing new insights into inflammatory pathways. Curr Drug Targets Inflamm Allergy 2005;4:67-76.
19. Touitou I, Notamicola C, Grandemange S. Identifying mutations in autoinflammatory diseases: Towards novel genetic tests and therapies. Am J Pharmacogenetics 2004;4:109-18.
20. Bernot A, da Silva C, Petit JL et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). Hum Mol Genet 1998;7:1317-25.
21. Tchernitchko D, Legendre M, Delahaye A et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. Clin Chem 2003;49:1942-5.
22. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972;287:1302.
23. Zemer D, Pras M, Scher E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001-5.
24. Onen F. Familial Mediterranean fever. Rheumatol Int 2006;26:489-96.
25. Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol 2006;24:435-7.
26. Calguneri M, Apras S, Ozbalkan Z, Ozturk MA. The efficacy of interferon-alpha in a patient with resistant familial Mediterranean fever complicated by polyarteritis nodosa. Intern Med 2004;43:612.
27. Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: Thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006;24(5 Suppl 42):S99-103.
28. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007;146:825-6.
29. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2007 [Epub ahead of print].
30. Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 2004;43:1405-8.
31. Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BHB, Toghill PJ. Familial Hibernian fever. Q J Med 1982;204:469-80.
32. McDermott EM, Smillie DM, Powell RJ. Clinical spectrum of familial Hibernian fever: A 14-year follow-up study of the index case and extended family. Mayo Clin Proc 1997;72:806-17.
33. Dodé C, André M, Bienvenu T et al. French Hereditary Recurrent Inflammatory Disorder Study Group: The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002;46:2181-8.
34. Masson C, Simon V, Hoppe E, Insalaco P, Cisse I, Audran M. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine 2004;71:284-90.
35. Hull KM, Wong K, Wood GM, Chu WS, Kastner DL. Monocytic fasciitis: A newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 2002;46:2189-94.
36. Manki A, Nishikomori R, Nakata-Hizume M et al. Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis. Allergol Int 2006;55:337-41.
37. Kümpfel T, Hoffmann LA, Rübsamen H et al. Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum 2007;56:2774-83.
38. Lamprecht P, Moosig F, Adam-Klages S et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2004;63:1518-20.
39. Kriegel MA, Huffmeier U, Scherb E et al. Tumor necrosis factor receptor-associated periodic syndrome characterized by a mutation affecting the cleavage site of the receptor: Implication for pathogenisis. Arthritis Rheum 2003;48:2386-8.
40. Ravet N, Rouaghe S, Dodé C et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006;65:1158-62.
41. Lobito AA, Kimberley FC, Muppidi JR et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006;108:1320-7.
42. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133.
43. D'Osualdo A, Ferlito F, Prigione I et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: Pathogenetic and clinical implications. Arthritis Rheum 2006;54:998-1008.
44. Haas SL, Lohse P, Schmitt WH et al. Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution. Gastroenterology 2006;130:172-8.
45. Drenth JP, van der Meer JVM. Hereditory periodic fever. N Engl J Med 2001; 345:1748-57.
46. Minden K, Aganna E, McDermott MF, Zink A. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 2004;63:1356-7.
47. Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 2004;43:1405-8.
48. Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 2007; 46:1211-2.
49. Van der Meer JWM, Vossen JM, Radl J et al. Hyperimmunoglobulinaemia D and periodic fever: A new syndrome. Lancet 1984;1:1087-90.
50. Drenth JP, Haagsma CJ, van der Meer JM. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD study group. Medicine 1994;73:133-44.
51. Armbrust S, Drenth JP, Schröder C, Domning E, Poeschl E, Wiersbitzky SK. Tendonitis in variant hyperimmunoglobulinaemia D and periodic fever syndrome - a rare disease with a new symptom. Eur J Pediatr 2005;164:391-4.
52. Armbrust S, Drenth JPH, Schroder C, Domning E, Poeschl E, Wiersbitzky SKW. Tendonitis in variant hyperimmunoglobulinaemia D and periodic fever syndrome - a rare disease with a new symptom. Eur J Pediatr 2005;164:391-4.
53. Drenth JP, Cuisset L, Grateau G et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 1999;22:178-81.
54. Houten SM, Kuis W, Duran M et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. Nat Genet 1999;22:175-7.
55. Bodar EJ, van der Hilst JC, van Heerde W, van der Meer JW, Drenth JP, Simon A. Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood 2007;109:2416-8.
56. Grateau G. Clinical and genetic aspects of the hereditory periodic fever syndromes. Rheumatology 2004;43:410-5.
57. Drenth JP, Göertz J, Daha MR, van der Meer JW. Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology 1996;88:355-62.
58. Houten SM, Koster J, Romeijn GJ et al. Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome. Eur J Hum Genet 2001;9:253-9.
59. Simon A, Drewe E, van der Meer JW et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004;75:476.
60. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51.
61. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model. Neth J Med 2005;63:260-4.
62. Curch LD, Churchman SM, Hawkins PN, McDermott MF. Hereditory autoinflammatory disorders and biologics. Springer Semin Immun 2006;27:494-508.
63. Mirault T, Launay D, Cuisset L et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006;54:1697-700.
64. McDermott MF, Frenkel J. Hereditary periodic fever syndromes. Neth J Med 2001;59:118-25.
65. Kilcline C, Shinkai K, Bree A, Modica R, Von Scheven E, Frieden IJ. Neonatal-onset multisystem inflammatory disorder: The emerging role of pyrin genes in autoinflammatory diseases. Arch Dermatol 2005;141:248-53.
66. Aksentijevich I, Putnam CD, Remmers EF et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273-85.
67. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26.
68. Sutterwala FS, Ogura Y, Szczepanik M et al. Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006;24:317-27.
69. Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006;440:228-32.
70. Matsubara T, Hasegawa M, Shiraishi M et al. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. Arthritis Rheum 2006;54:2314-20.
71. Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007;49:477-81.
72. Dalgic B, Egritas O, Sari S, Cuisset L. A variant Muckle-Wells syndrome with a novel mutation in CIAS1 gene responding to anakinra. Pediatr Nephrol 2007;22:1391-4.
73. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92.
74. O'Connell SM, O'Regan GM, Bolger T et al. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 2007; 24:85-9.
75. Merlini G, Bellott V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
76. van der Hilst JCH, Simon A, Drenth JPH. Hereditary periodic fever and reaction amyloidosis. Clin Exp Med 2005;5:87-98.
77. Yonem O, Bayrakta Y. Secondary amyloidosis due to FMF. Hepatogastroenterology 2007;54:1061-5.
78. Touitou I, Sarkisian T, Medlej-Hashim M et al. International Study Group for phenotype-genotype correlation in familial Mediterranean fever: Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-12.
79. Kallinich T, Briese S, Roesler J et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 2004;31:2519-22.
80. Obici L, Manno C, Muda AO et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004;50:2966-9.
81. Schwarz RE, Dralle H, Linke RP, Nathrath WB, Neumann KH. Amyloid goiter and arthritides after kidney transplantation in a patient with systemic amyloidosis and Muckle-Wells syndrome. Am J Clin Pathol 1989;92:821-5.
82. Gertz MA, Kyle RA. Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine 1991;70:246-56.